03/06/20
Bell Potter rates ((CYC)) as Buy (1) –
Cyclopharm has taken steps towards getting regulatory approval from the US, filing for a 505(b)2 registration for Technegas.
Technegas is helpful for diagnosing covid-19 patients with acute respiratory distress syndrome and aids in understanding how much a patient’s respiratory has been impacted.
The company raised $9.7m in December 2019 with the funds used to establish US operations later this year. Revenue estimates have been reduced for FY20-21 due to delay in launching the US operations.
Bell Potter leaves the rating unchanged at Buy along with an unchanged target of $1.77.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.020(1.97%) |
Mkt cap ! $110.5M | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.02 | 99.5¢ | $33.22K | 33.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 5274 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| CYC (ASX) Chart |